Safety and Efficacy of Etanercept Monotherapy for Moderate-to-severe Plaque Psoriasis: A Prospective 12-week Follow-up Study / 华中科技大学学报(医学)(英德文版)
Journal of Huazhong University of Science and Technology (Medical Sciences)
; (6): 943-947, 2017.
Article
ي Zh
| WPRIM
| ID: wpr-333399
المكتبة المسؤولة:
WPRO
ABSTRACT
Etanercept has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis.Since most clinical trials examined etanercept in combination with other drugs,the efficacy and safety of etanercept monotherapy for moderate-to-severe plaque psoriasis have not been well established.This prospective study enrolled 61 Chinese patients with moderate-to-severe plaque psoriasis to explore the efficacy and safety of etanercept monotherapy.These patients were treated with etanercept at a subcutaneous dose of 25 mg,twice a week,for 12 weeks.All the 61 patients completed the treatment and showed significant improvement in psoriasis area and severity index (PASI) scores.At 4,8,and 12 weeks after treatment,the response rates (PASI75) were 0%,21.31%,and 40.98%,respectively.It was concluded that etanercept monotherapy is efficacious and safe for patients with moderate-to-severe plaque psoriasis.
النص الكامل:
1
الفهرس:
WPRIM
نوع الدراسة:
Observational_studies
/
Prognostic_studies
اللغة:
Zh
مجلة:
Journal of Huazhong University of Science and Technology (Medical Sciences)
السنة:
2017
نوع:
Article